... Not everyone with IgA myeloma has severe disease, but overall, it tends to grow or spread more quickly than other types, such as IgG myeloma.If your oncology team believes your multiple myeloma is more aggressive, this may influence the treatment plan they recommend.Why Is IgA Myeloma More Aggressive? ...
IgG and IgA Antibodies in Myeloma: Which Is More Aggressive?
... Not everyone with IgA myeloma has severe disease, but overall, it tends to grow or spread more quickly than other types, such as IgG myeloma.If your oncology team believes your multiple myeloma is more aggressive, this may influence the treatment plan they recommend.Why Is IgA Myeloma More Aggressive? ...
... In those cases, a person affected would require additional treatment.Relative to solitary plasmacytoma, multiple myeloma has an overall worse prognosis (outlook). After initial treatment success, most patients relapse, and cancer will reappear after time. The five-year survival rate is approximately 50 percent. ...
Solitary Plasmacytoma vs. Myeloma: How Are They Different?
... In those cases, a person affected would require additional treatment.Relative to solitary plasmacytoma, multiple myeloma has an overall worse prognosis (outlook). After initial treatment success, most patients relapse, and cancer will reappear after time. The five-year survival rate is approximately 50 percent. ...
... Here are a few of the key takeaways from the survey:Myeloma has a broad impact on quality of life, as well as on emotional well-being.The majority of members surveyed are actively managing myeloma, including having meaningful conversations with their doctors, learning about and staying on recommended treatments, and seeking information to manage symptoms ...
Nearly Half of MyMyelomaTeam Members Say They Feel Isolated and Alone
... Here are a few of the key takeaways from the survey:Myeloma has a broad impact on quality of life, as well as on emotional well-being.The majority of members surveyed are actively managing myeloma, including having meaningful conversations with their doctors, learning about and staying on recommended treatments, and seeking information to manage symptoms ...
... therapy is a form of hormone replacement therapy (HRT) used to treat symptoms of menopause, such as hot flashes or vaginal dryness.Drugs that contain different forms of estrogen include: Pills — Estrace, Premarin Vaginal rings — Estring, Femring Vaginal inserts — Imvexxy, Vagifem Creams — Estrace, Premarin Patches — Climara, Menostar, Minivelle, Vivelle-Dot ...
Can Certain Medications Raise the Risk for Developing Myeloma?
... therapy is a form of hormone replacement therapy (HRT) used to treat symptoms of menopause, such as hot flashes or vaginal dryness.Drugs that contain different forms of estrogen include: Pills — Estrace, Premarin Vaginal rings — Estring, Femring Vaginal inserts — Imvexxy, Vagifem Creams — Estrace, Premarin Patches — Climara, Menostar, Minivelle, Vivelle-Dot ...
... Don’t forget that avoiding bad habits — such as smoking and excessive drinking — that negatively impact your mental health is just as important as implementing healthy ones.One MyMyelomaTeam member expressed the importance of adjusting diet as you go: “Diet and exercise seem to be the only things that help me. ...
Creating a Positive Outlook While Living With Myeloma
... Don’t forget that avoiding bad habits — such as smoking and excessive drinking — that negatively impact your mental health is just as important as implementing healthy ones.One MyMyelomaTeam member expressed the importance of adjusting diet as you go: “Diet and exercise seem to be the only things that help me. ...
... Immunotherapy is now really providing hope to a lot of patients with cancers that were not really responding to our standard chemotherapies," Sabel said.CAR T-cell therapy previously has been used to treat lymphoma and lymphocytic leukemia, Lichtenfeld said.Zhao and his colleagues decided to try the therapy to treat multiple myeloma. ...
Gene-Based Therapy May Thwart a Tough Blood Cancer
... Immunotherapy is now really providing hope to a lot of patients with cancers that were not really responding to our standard chemotherapies," Sabel said.CAR T-cell therapy previously has been used to treat lymphoma and lymphocytic leukemia, Lichtenfeld said.Zhao and his colleagues decided to try the therapy to treat multiple myeloma. ...
... It has been proved that socioeconomic factors — like education, income, and the environments that people live in — affect people’s health in many ways. The U.S. government has designed plans to address these health disparities and inequities. ...
... Some patients like it; some patients say, “It’s just too much for me. I don’t want to commit myself.”I don’t think many of our patients have a problem with it. In fact, they like this additional safety net and having the attention of this team.Are Clinical Trials the Last Option for Treating Blood Cancer? ...
Are We Close to a Cure for Blood Cancer? Dr. Nowakowski Weighs In
... Some patients like it; some patients say, “It’s just too much for me. I don’t want to commit myself.”I don’t think many of our patients have a problem with it. In fact, they like this additional safety net and having the attention of this team.Are Clinical Trials the Last Option for Treating Blood Cancer? ...
... What works for me is placing a heating pad in the area of the cramp. Also, if at all possible, I get out of bed and try to walk it out.” “What works for me is placing a heating pad in the area of the cramp. ...
... Most responses began in a little more than a month. Responses lasted nine months in 85 percent of people, based on pooled results from different dosing schedules. These trial results show that BiTE drugs are offering new hope for people with relapsed or refractory multiple myeloma. ...
Join
